Keytruda (pembrolizumab)

pCPA File Number: 22014
Negotiation Status:
Active Negotiation
Indication(s):
in combination with Lenvatinib (Lenvima) for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0288
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable